Printer Friendly

Can you predict myocardial uptake of F-18 fluoro-deoxy-glucose (FDG) from fasting plasma glucose?

Positron emission tomography (PET) using F-18 fluoro-deoxyglucose (FDG) has become a very powerful tool for myocardial viability determination. Plasma glucose is usually determined prior to myocardial imaging with FDG. Some centers routinely use insulin-clamp (insulin after a glucose load) while others rely on fasting glucose. The purpose of this investigation was to determine if the fasting glucose can predict myocardial uptake of FDG. This study population included 49 patients (mean age 60 [+ or -] 14 years) who had undergone FDG whole body PET scans for variety of indications. The mean injected activity of FDG was 18 [+ or -] 2.5 mCi. These images were retrospectively analyzed to determine myocardial uptake of FDG. The LV region of interest was demarcated and average selective uptake value (SUV) was determined and correlated with the fasting plasma glucose levels. The data analysis showed no correlation between fasting glucose and average SUV. The fasting plasma glucose ranged from 50-354 mg/dl (mean of 103 [+ or -] 42). The SUV ranged from 1.14 to 9.71 (mean 2.92 [+ or -] 1.89). A regression coefficient of -0.008 indicated no correlation between fasting glucose and average SUV. For further analysis, the patients (pts) were divided into two groups based on plasma glucose. In group A, there were 29 pts with glucose level 50-100, and in group B, there were 20 pts with glucose level 100-354. The mean SUV was 3.22 [+ or -] 2.17 and 2.49 [+ or -] 1.27 in groups A and B, respectively, and the difference was statistically significant (P = 0.03). However, this small difference in SUV is probably clinically insignificant. We conclude that fasting plasma glucose measured prior to myocardial imaging with FDG do not predict myocardial uptake of FDG. We question the usefulness of the practice of using fasting plasma glucose and prefer to use insulin clamp technique, with excellent results.

Amolak Singh, MD, FACP, FACNM, and Aju Thomas, MD. University of Missouri Health Care, Columbia, MO.
COPYRIGHT 2004 Southern Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Section on Radiology
Author:Thomas, Aju
Publication:Southern Medical Journal
Date:Oct 1, 2004
Previous Article:Radiological signs of Paget's disease.
Next Article:Manifestations of skeletal syphilis from new born to adulthood.

Related Articles
Importance of Postprandial Glucose Control.
Positron emission tomography in laryngeal cancer.
Physiological localization of F-18 fluoro-deoxyglucose (FDG): a potential source of false-positive FDG scans for cancer.
Rad-9. Increased incidence of heterogeneous appearance of liver on whole body F-18 FDG PET imaging in heavier patients.
Fluorodeoxyglucose F 18 positron emission tomography scanning in thoracic disease.
Diagnosis of benign solitary fibrous tumors by positron emission tomography.
The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience.
Strategies for insulin therapy in type 2 diabetes.
Giant cell arteritis mimicking multiple myeloma; diagnosed by PET scan.
The role of positron emission tomography for the diagnosis and follow up of a patient with sarcoidosis and Takayasu arteritis.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters